<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00336154</url>
  </required_header>
  <id_info>
    <org_study_id>2140CTIL</org_study_id>
    <nct_id>NCT00336154</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa</brief_title>
  <official_title>Randomised Double Blind Crossover Placebo Controlled Study to Evaluate the Efficacy of Tetracycline in Epidermolysis Bullosa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Rambam Health Care Campus</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Rambam Health Care Campus</source>
  <brief_summary>
    <textblock>
      Epidermolysis Bullosa(EB) is an inherited bullous disease. Tetracycline is believed to have&#xD;
      anti inflammatory properties. 20 patients with EB older than 13 years will be treated for 4&#xD;
      months with tetracycline or placebo. After one month of wash out they will be treated for&#xD;
      additional 4 m with placebo or tetracycline. The patients will be examined each month to&#xD;
      estimate bulla formation,rate of healing .&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Epidermolysis Bullosa(EB) is an inherited bullous disease. Tetracycline is believed to have&#xD;
      anti inflammatory properties. 20 patients with EB older than 13 years will be treated for 4&#xD;
      months with tetracycline or placebo. After one month of wash out they will be treated for&#xD;
      additional 4 m with placebo or tetracycline. The patients will be examined each month to&#xD;
      estimate bulla formation,rate of healing .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Withdrawn</overall_status>
  <primary_completion_date type="Anticipated">June 2006</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>no of blisters</measure>
  </primary_outcome>
  <enrollment type="Actual">0</enrollment>
  <condition>Epidermolysis Bullosa</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>tetracyclin</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  diagnosed as epidermolysis bullosa&#xD;
&#xD;
          -  not pregnant&#xD;
&#xD;
          -  active disease&#xD;
&#xD;
          -  more than 5 bulla-&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  age less than 13&#xD;
&#xD;
          -  known sensitivity to tetracyclin&#xD;
&#xD;
          -  abnormal liver and kidney tests.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>13 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <removed_countries>
    <country>Israel</country>
  </removed_countries>
  <verification_date>October 2020</verification_date>
  <study_first_submitted>June 12, 2006</study_first_submitted>
  <study_first_submitted_qc>June 12, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 13, 2006</study_first_posted>
  <last_update_submitted>October 27, 2020</last_update_submitted>
  <last_update_submitted_qc>October 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">October 28, 2020</last_update_posted>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epidermolysis Bullosa</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tetracycline</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

